EA201600442A1 - Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол - Google Patents

Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол

Info

Publication number
EA201600442A1
EA201600442A1 EA201600442A EA201600442A EA201600442A1 EA 201600442 A1 EA201600442 A1 EA 201600442A1 EA 201600442 A EA201600442 A EA 201600442A EA 201600442 A EA201600442 A EA 201600442A EA 201600442 A1 EA201600442 A1 EA 201600442A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
water basis
containing tapentadol
basis containing
soft pharmaceutical
Prior art date
Application number
EA201600442A
Other languages
English (en)
Other versions
EA033171B1 (ru
Inventor
Ульрих Райнхольд
Марк Шиллер
Эва Вульстен
Сабине Карине Катрин Ингхельбрехт
Роже Каролус Аугуста Эмбрехтс
Ульрих Файль
Original Assignee
Грюненталь Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Грюненталь Гмбх filed Critical Грюненталь Гмбх
Publication of EA201600442A1 publication Critical patent/EA201600442A1/ru
Publication of EA033171B1 publication Critical patent/EA033171B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Изобретение относится к мягкой фармацевтической композиции на водной основе, содержащей тапентадол или его физиологически приемлемую соль.
EA201600442A 2011-03-04 2012-03-02 Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол EA033171B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161449329P 2011-03-04 2011-03-04
EP11003603 2011-05-03

Publications (2)

Publication Number Publication Date
EA201600442A1 true EA201600442A1 (ru) 2017-02-28
EA033171B1 EA033171B1 (ru) 2019-09-30

Family

ID=44652117

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201600442A EA033171B1 (ru) 2011-03-04 2012-03-02 Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол
EA201300988A EA025194B1 (ru) 2011-03-04 2012-03-02 Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201300988A EA025194B1 (ru) 2011-03-04 2012-03-02 Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол

Country Status (24)

Country Link
US (3) US9446008B2 (ru)
EP (3) EP3290029B1 (ru)
JP (3) JP6027549B2 (ru)
KR (2) KR102039320B1 (ru)
CN (1) CN103501774A (ru)
AU (2) AU2012224954C1 (ru)
BR (1) BR112013022556A8 (ru)
CA (1) CA2828637C (ru)
CY (1) CY1119725T1 (ru)
DK (1) DK2680834T3 (ru)
EA (2) EA033171B1 (ru)
ES (2) ES2910085T3 (ru)
HR (1) HRP20171836T1 (ru)
HU (1) HUE037491T2 (ru)
IL (2) IL227826B (ru)
LT (1) LT2680834T (ru)
MX (1) MX344473B (ru)
NO (1) NO2680834T3 (ru)
PL (1) PL2680834T3 (ru)
PT (2) PT3766489T (ru)
RS (1) RS56692B1 (ru)
SI (1) SI2680834T1 (ru)
WO (1) WO2012119729A1 (ru)
ZA (1) ZA201306480B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9446008B2 (en) * 2011-03-04 2016-09-20 Gruenenthal Gmbh Semisolid aqueous pharmaceutical composition containing tapentadol
RS59491B1 (sr) 2011-03-04 2019-12-31 Gruenenthal Gmbh Vodena farmaceutska formulacija tapentadola za oralnu primenu
US8997860B2 (en) 2011-08-05 2015-04-07 Halliburton Energy Services, Inc. Methods for monitoring the formation and transport of a fracturing fluid using opticoanalytical devices
US9395306B2 (en) 2011-08-05 2016-07-19 Halliburton Energy Services, Inc. Methods for monitoring fluids within or produced from a subterranean formation during acidizing operations using opticoanalytical devices
US8619256B1 (en) 2012-09-14 2013-12-31 Halliburton Energy Services, Inc. Systems and methods for monitoring the properties of a fluid cement composition in a flow path
US9228940B2 (en) 2012-09-14 2016-01-05 Halliburton Energy Services, Inc. Systems, methods, and apparatuses for in situ monitoring of cement fluid compositions and setting processes thereof
US20140076550A1 (en) 2012-09-14 2014-03-20 Halliburton Energy Services, Inc. Systems and Methods for Detecting Microannulus Formation and Remediation
WO2015014980A1 (en) * 2013-08-02 2015-02-05 Ratiopharm Gmbh Composition comprising tapentadol in a dissolved form
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
JP6923447B2 (ja) * 2015-03-27 2021-08-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口投与のための安定な製剤
AU2017329964B2 (en) * 2016-09-23 2022-10-06 Grünenthal GmbH Stable formulation for parenteral administration of Tapentadol
EP3826631A1 (en) * 2018-07-24 2021-06-02 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical emulsion of an anticholinergic compound

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775678A (en) * 1984-10-01 1988-10-04 Schering Corporation Clotrimazole cream
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6183758B1 (en) * 1998-01-29 2001-02-06 Highland Laboratories, Inc. Phytochemicals, nutrients & medication absorption &/or treatment
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
US20050176790A1 (en) * 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
WO2003077897A1 (en) 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
US20030191187A1 (en) 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
AU2003275329B2 (en) 2002-09-13 2008-04-03 Cydex Pharmaceuticals, Inc. Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
US20040180915A1 (en) 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
JP2007538091A (ja) 2004-05-17 2007-12-27 ファーマコフォア・インコーポレイテッド 痛みを処置または予防するための組成物および方法
EP1612203B1 (en) 2004-06-28 2007-08-01 Grünenthal GmbH Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
EP1786403B1 (de) 2004-07-01 2013-07-24 Grünenthal GmbH Gegen missbrauch gesicherte, orale darreichungsform enthaltend (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
CN101208081A (zh) 2005-04-28 2008-06-25 谢拉奎斯特生物科学有限公司 治疗疼痛的方法和组合物
TWI329334B (en) 2005-12-02 2010-08-21 Chung Shan Inst Of Science Manufacture method of electromagnetic interference layer for the plasma display panel
WO2007127158A2 (en) * 2006-04-25 2007-11-08 Croda, Inc Modification of percutaneous absorption of topically active materials
PL2012764T3 (pl) 2006-04-28 2011-04-29 Gruenenthal Gmbh Kombinacja farmaceutyczna zawierająca 3-(3-dimetyloamino-1-etylo-2-metylopropylo)fenol i Paracetamol
AU2007247480B8 (en) 2006-04-28 2013-04-11 Grunenthal Gmbh Pharmaceutical combination comprising 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and an NSAID
DE602007004494D1 (de) 2006-07-24 2010-03-11 Janssen Pharmaceutica Nv Herstellung von (2r,3r)-3-(3-methoxyphenyl)-n,n,2- trimethylpentanamin
DE102007012165A1 (de) * 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
KR101972299B1 (ko) * 2007-11-23 2019-08-16 그뤼넨탈 게엠베하 타펜타돌 조성물
AU2009207796B2 (en) 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
BRPI0921725A2 (pt) 2008-10-30 2016-01-05 Grüenthal GmbH formas de dosagem potentes do tapentadol
US20100227921A1 (en) 2009-03-03 2010-09-09 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
US20100272815A1 (en) 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
US20110190267A1 (en) * 2010-01-05 2011-08-04 Shire Pharmaceuticals, Inc. Prodrugs of opioids and uses thereof
RU2553350C2 (ru) * 2010-03-30 2015-06-10 Фосфейдженикс Лимитед Трансдермальные пластыри
GB201006200D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
US20120270848A1 (en) * 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
US9446008B2 (en) * 2011-03-04 2016-09-20 Gruenenthal Gmbh Semisolid aqueous pharmaceutical composition containing tapentadol

Also Published As

Publication number Publication date
JP2014506900A (ja) 2014-03-20
ZA201306480B (en) 2014-05-28
US9446008B2 (en) 2016-09-20
JP6670283B2 (ja) 2020-03-18
US20180133174A1 (en) 2018-05-17
PL2680834T3 (pl) 2018-03-30
EP2680834A1 (en) 2014-01-08
EA201300988A1 (ru) 2014-06-30
MX2013010100A (es) 2013-10-01
US20160346229A1 (en) 2016-12-01
MX344473B (es) 2016-12-16
AU2012224954B2 (en) 2016-10-20
EP3766489B1 (en) 2022-03-16
CA2828637A1 (en) 2012-09-13
EP3766489A1 (en) 2021-01-20
US20120225950A1 (en) 2012-09-06
AU2012224954A1 (en) 2013-09-19
EA025194B1 (ru) 2016-11-30
JP6259042B2 (ja) 2018-01-10
ES2654407T3 (es) 2018-02-13
PT3766489T (pt) 2022-04-07
KR20180116463A (ko) 2018-10-24
CY1119725T1 (el) 2018-06-27
ES2910085T3 (es) 2022-05-11
PT2680834T (pt) 2018-01-25
AU2017200040B2 (en) 2018-09-06
BR112013022556A8 (pt) 2018-01-16
SI2680834T1 (en) 2018-01-31
BR112013022556A2 (pt) 2016-12-06
IL227826A0 (en) 2013-09-30
LT2680834T (lt) 2018-01-10
IL258357A (en) 2018-05-31
IL227826B (en) 2018-04-30
KR20140013020A (ko) 2014-02-04
HRP20171836T1 (hr) 2017-12-29
CA2828637C (en) 2019-06-11
AU2012224954C1 (en) 2017-04-06
EP3290029B1 (en) 2020-09-02
EP3290029A1 (en) 2018-03-07
CN103501774A (zh) 2014-01-08
JP6027549B2 (ja) 2016-11-16
JP2018065839A (ja) 2018-04-26
EP2680834B1 (en) 2017-10-18
WO2012119729A1 (en) 2012-09-13
JP2017039756A (ja) 2017-02-23
AU2017200040A1 (en) 2017-02-02
KR101911362B1 (ko) 2018-10-25
EA033171B1 (ru) 2019-09-30
DK2680834T3 (en) 2017-12-04
NO2680834T3 (ru) 2018-03-17
RS56692B1 (sr) 2018-03-30
KR102039320B1 (ko) 2019-11-01
HUE037491T2 (hu) 2018-09-28

Similar Documents

Publication Publication Date Title
EA201600442A1 (ru) Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол
EA201390081A1 (ru) Дейтерированный n-этил-n-фенил-1,2-дигидро-4-гидрокси-5-хлор-1-метил-2-оксохинолин-3-карбоксамид, его соли и их применение
JP2014501485A5 (ru)
FR2962442B1 (fr) Composition stable de 2,3,3,3-tetrafluoropropene
EA201300989A1 (ru) Водная фармацевтическая композиция тапентадола для перорального введения
MX2013012542A (es) Compuestos de amida y aplicacion farmaceutica para el mismo.
ITMI20111404A1 (it) Supporto per articolazioni umane.
IT1400982B1 (it) Collirio osmotico trans-epiteliale per la cura del cheratocono.
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан
BR112015003259A2 (pt) composto, composição farmacêutica, e, composição de vacina.
EA201001710A3 (ru) Фармацевтическая композиция, которая содержит соль стронция, витамин d и циклодекстрин
EA201590296A1 (ru) Дейтерированный ибрутиниб
EA201600088A1 (ru) Парентеральное введение тапентадола
EA201390613A1 (ru) Обогащенный дейтерием расагилин
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
BR112014025041B8 (pt) Composição farmacêutica
BR112015005788A2 (pt) implante de articulação".
FR2973218B1 (fr) Plaque d'osteosynthese.
JP2013541099A5 (ru)
JP2013536184A5 (ru)
UY34553A (es) Procedimiento de preparación de la sal de l-arginina de perindoprilo
CO6920289A2 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib.
IT1397255B1 (it) Struttura di impianto dentale perfezionato.
BR112013030897A2 (pt) composição.
MX348786B (es) Agentes osmoticos de polisacarido esterificado.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU